Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
Warner K. Huh, Elmar A. Joura, Anna R. Giuliano, Ole Erik Iversen, Rosires Pereira de Andrade, Kevin A. Ault, Deborah Bartholomew, Ramon M. Cestero, Edison N. Fedrizzi, Angelica L. Hirschberg, Marie Hélène Mayrand, Angela Maria Ruiz-Sternberg, Jack T. Stapleton, Dorothy J. Wiley, Alex Ferenczy, Robert Kurman, Brigitte M. Ronnett, Mark H. Stoler, Jack Cuzick, Suzanne M. GarlandSusanne K. Kjaer, Oliver M. Bautista, Richard Haupt, Erin Moeller, Michael Ritter, Christine C. Roberts, Christine Shields, Alain Luxembourg
Dive into the research topics of 'Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial'. Together they form a unique fingerprint.